Mahamaya Lifesciences has accepted the resignation of Shilpi Bhardwaj as Company Secretary, Compliance Officer, and Key Managerial Personnel (KMP). The departure is effective July 30, 2026, with Bhardwaj citing alternate career opportunities outside the organization as the reason for her exit. The company confirmed that there are no material reasons for her resignation other than those stated.

The Board of Directors approved the resignation on July 30, 2026. Bhardwaj submitted her resignation letter dated June 10, 2026, under the provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and the Companies Act, 2013. She will be relieved from her duties at the close of business hours on July 30, 2026.

Resignation Details

Bhardwaj confirmed in her resignation letter that she would extend all necessary assistance and cooperation to ensure a smooth handover of responsibilities during the notice period. The company disclosed the change pursuant to Regulation 30 read with Paragraph A, Part A of Schedule III of the SEBI Listing Regulations, 2015.

Krishnamurthy Ganesan, Managing Director of Mahamaya Lifesciences, signed the intimation to BSE Limited. The filing included Annexure A detailing the event and the resignation letter. No other material changes in key managerial personnel were reported alongside this announcement.

Mahamaya Lifesciences Limited reported a 29% year-on-year increase in profit after tax (PAT) to ₹1,652.33 lakh for the fiscal year ended March 31, 2026, driven by a 24.5% rise in revenue from operations to ₹32,887.30 lakh. The agrochemical company's EBITDA surged 32.06% to ₹3,425.88 lakh, with margins expanding by 60 basis points to 10.42%, reflecting improved operational efficiencies despite significant accounting adjustments related to its recent listing.

Financial Performance

The company's revenue growth was supported by strong performance across both halves of the fiscal year. H2 FY26 revenue reached ₹16,580.93 lakh, slightly higher than H1 FY26's ₹16,306.37 lakh. Profitability was impacted by approximately ₹411 lakh in adjustments, including an unrealized forex loss of ₹264.16 lakh, an exchange difference of ₹125.25 lakh, and listing-related expenses of ₹21.57 lakh. The diluted earnings per share (EPS) for FY26 stood at ₹8.33, compared to ₹7.52 in the previous year.

Consolidated Results

The consolidated financial results include the performance of its subsidiary, Mahamaya Lifesciences (FZE), based in the UAE. Total income for the year stood at ₹33,003.23 lakh. The board approved the audited standalone and consolidated financial results during a meeting on May 25, 2026.

Key Financial Metrics

The following table summarizes the consolidated financial performance for FY26:

Operational Outlook

Mr. Prashant Krishnamurthy, Executive Director, highlighted the company's focus on expanding its sustainable and biological crop care portfolio. The company is strengthening its presence in domestic and export markets, leveraging its modern Dahej facility for large-scale production and R&D innovation to ensure regulatory compliance under BIS and FAO standards.